Esperion to Participate in Jefferies Global Healthcare Conference - London

Rhea-AI Summary

Esperion (NASDAQ: ESPR) will present at the Jefferies Global Healthcare Conference – London on November 18, 2025 at 8:00 a.m. GMT (3:00 a.m. ET).

The presentation will be webcast live and accessible via the company investor website. A replay will be available approximately two hours after the call and will be archived on the company website for approximately 90 days. Esperion is a commercial-stage biopharmaceutical company developing oral, once-daily, non-statin medicines for patients with elevated LDL-C and is advancing next-generation ACLY inhibitor programs supported by prior CLEAR outcomes research.

News Market Reaction – ESPR

-0.67%

-0.67% Session close to close

In the Nov 3 session, ESPR declined 0.67%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ANN ARBOR, Mich., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Jefferies Global Healthcare Conference – London on November 18, 2025, at 8:00 a.m. GMT (3:00 a.m. ET).

The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When will Esperion (ESPR) present at the Jefferies Global Healthcare Conference London?

Esperion will present on November 18, 2025 at 8:00 a.m. GMT (3:00 a.m. ET).

How can investors watch the Esperion (ESPR) Jefferies conference presentation?

The presentation will be available via a live webcast on the company investor and media website.

When will the replay of the Esperion (ESPR) webcast be available and for how long?

A replay will be available about two hours after the call and will be archived for approximately 90 days.

What time is the Esperion (ESPR) presentation in Eastern Time?

The presentation is at 3:00 a.m. ET on November 18, 2025.

What topics will Esperion (ESPR) cover in the Jefferies presentation?

The company will discuss its commercial-stage programs for oral non-statin LDL-C medicines and its next-generation ACLYi research and development efforts.

Where can I find contact details for Esperion investor relations regarding the conference?

Investor inquiries can be directed to the investor relations contact listed on the company website and in the conference notice.